2025 in Review: RegMed XB Highlights
RegMed XB’s 2025 marked another year of strong progress and growing. Regenerative medicine continued as a key approach to addressing the rising burden of chronic diseases, supported by expanding collaborations and concrete translational advances.
Bernard Mulder, General Director RegMed XB